Article
New York - With the results of two previous open trials supporting clinical use of tacrolimus (Protopic) and pimecrolimus (Elidel), current data affirms that the topical immunomodulators are the definitive treatment of choice for facial and intertriginous psoriasis, according to Mark Lebwohl, M.D.